Low-Dose Naltrexone (LDN): Clinical Overview for Providers

Low-dose naltrexone refers to naltrexone prescribed at roughly 1.5 to 4.5 mg daily, compared with the 50 mg dose approved for alcohol and opioid dependence. It is not a peptide — it appears in this formulary because it is routinely combined with peptide protocols in the inflammatory and autoimmune conditions where both are used.

This guide situates Low-Dose Naltrexone (LDN) within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What LDN is

Naltrexone is a competitive opioid receptor antagonist, FDA-approved at 50 mg daily for alcohol use disorder and opioid dependence, where the goal is sustained blockade.

LDN uses roughly one-tenth of that dose, typically 1.5 to 4.5 mg, most often taken at night. At this dose the intent is the opposite of sustained blockade — and the proposed mechanisms depend entirely on the dose being low.

Because no commercial product exists at these strengths, LDN is prepared by compounding pharmacies. Naltrexone itself is an approved drug with a long safety record, which places LDN in a different position from unapproved research chemicals: the molecule is well characterized, the pharmacology is understood, and the dose and indication are off-label.

The two proposed mechanisms

Transient opioid blockade with endorphin rebound. A low dose produces brief receptor blockade lasting a few hours. The body is proposed to respond by upregulating endogenous opioid production and receptor expression. As the drug clears, the patient is left with an enhanced endogenous opioid system. This is why timing and low dosing matter: sustained blockade at 50 mg would prevent any such rebound from being expressed.

TLR4 antagonism on glial cells. This mechanism is separate from opioid receptors entirely. Naltrexone — and particularly its (+) stereoisomer — antagonizes Toll-like receptor 4 on microglia, the central nervous system's resident immune cells. TLR4 activation drives microglial release of pro-inflammatory cytokines, a process implicated in central sensitization and chronic pain states.

The TLR4 mechanism is the more compelling of the two for inflammatory and pain indications, and it explains why LDN is investigated in conditions characterized by neuroinflammation rather than peripheral tissue damage.

It is a genuinely interesting example of dose-dependent mechanism reversal: the same molecule doing something different, not merely less, at a lower dose.

What the trials show

The strongest signals come from fibromyalgia, where small randomized and crossover trials have reported reductions in pain scores compared with placebo. These are small studies from a limited number of groups, but the results have been reasonably consistent, and fibromyalgia's proposed central sensitization mechanism fits the TLR4 rationale.

In Crohn's disease, small placebo-controlled trials have reported improvement in disease activity scores and, in some work, endoscopic findings. Again the studies are small.

LDN has also been studied in multiple sclerosis, with results generally showing effects on quality-of-life measures rather than disease-modifying outcomes, and it has been examined in complex regional pain syndrome and various autoimmune conditions with weaker and more preliminary evidence.

The honest overall assessment: consistent small-scale signals in a few conditions, without the large trials that would establish efficacy definitively. The literature is more substantial than for most compounds in this formulary and considerably less substantial than for an approved therapy in these indications.

Practical considerations

The safety profile at low dose is favorable, with vivid dreams and sleep disturbance the most commonly reported effects, often transient.

One consideration is absolute: LDN is an opioid antagonist, so it is contraindicated in patients taking opioid analgesics, in whom it will precipitate withdrawal and block analgesia. This must be screened for explicitly, and patients must understand that it also affects opioid analgesia in an emergency.

Because LDN is compounded, formulation quality varies between pharmacies, and reliable low-dose accuracy matters at these strengths.

Prescribing is off-label, and patients deserve to be told that plainly: an approved medication, used at an unapproved dose for an unapproved indication, supported by small trials with encouraging but not definitive results. For many patients with fibromyalgia who have exhausted better-established options, that is a reasonable conversation — provided it is an accurate one.